These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 38686320)

  • 1. The gut-liver axis in fatty liver disease: role played by natural products.
    Ming Z; Ruishi X; Linyi X; Yonggang Y; Haoming L; Xintian L
    Front Pharmacol; 2024; 15():1365294. PubMed ID: 38686320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis.
    Han H; Jiang Y; Wang M; Melaku M; Liu L; Zhao Y; Everaert N; Yi B; Zhang H
    Crit Rev Food Sci Nutr; 2023; 63(12):1689-1706. PubMed ID: 34404276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
    Ni Y; Ni L; Zhuge F; Fu Z
    Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut-Liver Axis.
    Chen X; Liu M; Tang J; Wang N; Feng Y; Ma H
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
    Song Q; Zhang X
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.
    Luo L; Chang Y; Sheng L
    Life Sci; 2023 May; 321():121614. PubMed ID: 36965522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
    Castelnuovo G; Perez-Diaz-Del-Campo N; Guariglia M; Poggiolini I; Armandi A; Rosso C; Caviglia GP; Bugianesi E
    Minerva Gastroenterol (Torino); 2023 Mar; ():. PubMed ID: 36892817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.
    Arab JP; Arrese M; Shah VH
    Hepatol Res; 2020 Apr; 50(4):407-418. PubMed ID: 31840358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.
    Park JW; Kim SE; Lee NY; Kim JH; Jung JH; Jang MK; Park SH; Lee MS; Kim DJ; Kim HS; Suk KT
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease.
    Ni Y; Lu M; Xu Y; Wang Q; Gu X; Li Y; Zhuang T; Xia C; Zhang T; Gou XJ; Zhou M
    Front Microbiol; 2022; 13():908011. PubMed ID: 35832821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis.
    Takayama S; Katada K; Takagi T; Iida T; Ueda T; Mizushima K; Higashimura Y; Morita M; Okayama T; Kamada K; Uchiyama K; Handa O; Ishikawa T; Yasukawa Z; Okubo T; Itoh Y; Naito Y
    World J Gastroenterol; 2021 May; 27(18):2160-2176. PubMed ID: 34025071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-Microbiota Interactions in Liver Inflammation and Cancer.
    Giraud J; Saleh M
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Beneficial Effects of Natural Extracts and Bioactive Compounds on the Gut-Liver Axis: A Promising Intervention for Alcoholic Liver Disease.
    Zhao L; Wang S; Zhang N; Zhou J; Mehmood A; Raka RN; Zhou F; Zhao L
    Antioxidants (Basel); 2022 Jun; 11(6):. PubMed ID: 35740108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids.
    Sun Q; Xin X; An Z; Hu Y; Feng Q
    Front Cell Infect Microbiol; 2022; 12():854879. PubMed ID: 35356532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.
    An L; Wirth U; Koch D; Schirren M; Drefs M; Koliogiannis D; Nieß H; Andrassy J; Guba M; Bazhin AV; Werner J; Kühn F
    J Gastrointest Surg; 2022 Mar; 26(3):671-683. PubMed ID: 34734369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.